WuXi AppTec posts lower profits but avoids more share price pain
The pharmaceutical services giant delivered lackluster half-year earnings, with revenues and profits both falling, but investors were relieved that its U.S. business took only a minor hit Key Takeaways: U.S.…
Recent Articles
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK
603259.SHG
RELATED ARTICLES
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG -
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK
-
China-focused Tigermed staves off biopharma gloom
3347.HK 300347.SHE
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
- CHINA BULLETIN: Manufacturing Déjà Vu
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
